---

ROPINIROLE - Drug Presentation

---

1. MECHANISM OF ACTION

• These D2 receptors are G-protein-coupled inhibitory neurons located primarily in the striatonigral, mesolimbic, and tuberoinfundibular systems
• Ropinirole binding inhibits adenylyl cyclase and calcium channels, and activates potassium channels
• In Parkinson's disease, it mimics the action of dopamine in the depleted nigrostriatal pathway, maximizing "on" time and minimizing "off" time
• It binds approximately 20x more selectively to D3 than D2 receptors (unlike bromocriptine which has a ratio <2:1)
• In Restless Legs Syndrome (RLS), the precise mechanism is less clear but is also thought to be related to dopamine receptor stimulation

---

2. INDICATIONS

1. Parkinson's Disease (PD) - both early and advanced stages; can be used as monotherapy or adjunct to levodopa
2. Restless Legs Syndrome (RLS) - moderate to severe primary RLS (FDA-approved)
3. Off-label: Antidepressant-induced sexual dysfunction; fibromyalgia; periodic limb movement disorder (PLMD)

---

3. DOSAGE

Parkinson's Disease (Immediate-Release Tablets)

Restless Legs Syndrome

• Renal impairment (ESRD on hemodialysis): Starting dose 0.25 mg TID for PD; max 18 mg/day. Supplemental doses after dialysis are not required.
• Hepatic impairment: Use with caution; titrate slowly as ropinirole is hepatically metabolized.
• Elderly: Titrate more slowly due to higher risk of hallucinations, nausea, and vomiting.

---

4. ROUTE OF ADMINISTRATION

• Oral (primary route) - tablets (immediate-release and extended-release)
• Available as: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg tablets (IR); 2 mg, 4 mg, 6 mg, 8 mg, 12 mg (XL)

---

5. FREQUENCY

• Parkinson's disease (IR): Three times daily (TID) with meals to reduce nausea
• RLS (IR): Once daily, 1 to 3 hours before bedtime
• Extended-release (XL/ER): Once daily for Parkinson's disease
• Steady-state concentrations are reached within 2 days of dosing

---

6. STORAGE

• Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) - USP Controlled Room Temperature
• Protect from light and moisture
• Keep container tightly closed after each use
• Keep out of reach of children

---

7. PHARMACOKINETICS

• CYP1A2 inhibitors (fluoroquinolones, fluvoxamine, ciprofloxacin): increase ropinirole plasma levels - dose reduction may be needed
• Estrogens: inhibit CYP1A2, may increase ropinirole levels
• CYP1A2 inducers (smoking, omeprazole): decrease ropinirole levels - dose increase may be needed if patient stops smoking

---

8. PHARMACODYNAMICS

• Stimulates dopamine D2/D3 receptors in the striatum, reproducing the inhibitory effects of endogenous dopamine
• Suppresses serum prolactin concentrations (at doses ≥0.8 mg)
• Causes orthostatic hypotension via D2-mediated blunting of the noradrenergic response to standing, leading to decreased peripheral vascular resistance
• No effect on ECG wave form or rhythm at therapeutic doses
• Compared to levodopa: fewer dyskinesias (motor complications); at 5 years, ropinirole caused motor complications in only 20% of patients vs. 45% with levodopa

---

9. CONTRAINDICATIONS

• Hypersensitivity to ropinirole or any excipient (rash, pruritus, urticaria, angioedema, anaphylaxis)

• Alcohol abuse - increased CNS depression risk
• Severe hepatic failure - impaired metabolism
• History of psychosis or schizophrenia - may worsen hallucinations/psychosis
• Severe cardiovascular disease - risk of orthostatic hypotension and syncope
• Pregnancy (Category C) - use only if benefit outweighs risk
• Breastfeeding - ropinirole suppresses prolactin and may impair lactation; an alternative drug is preferred for nursing mothers
• Pediatric patients - safety and efficacy not established

---

10. ADVERSE EFFECTS / SIDE EFFECTS

Common (>10%)

• Nausea (most frequent)
• Vomiting, dyspepsia, abdominal pain
• Dizziness / somnolence
• Fatigue, asthenic conditions (weakness, malaise)
• Orthostatic hypotension - especially during dose escalation

Nervous System

• Hallucinations (more common in elderly)
• Confusion, dyskinesia (less frequent than levodopa)
• Sudden-onset sleep attacks - "sleep attacks" without warning; major safety concern especially while driving
• Insomnia

Cardiovascular

• Orthostatic hypotension, syncope
• Bradycardia (transient sinus arrest reported in healthy volunteers in clinical trials)
• Leg edema

Impulse Control Disorders (important - often underreported)

• Pathological gambling
• Hypersexuality / increased libido
• Compulsive shopping or eating (binge eating)
• Mechanism: thought to be stimulation of dopamine D3 receptors; patients may not report due to embarrassment - clinicians must proactively ask

Other

• Viral infections
• Augmentation (in RLS - worsening of symptoms)
• Manic symptoms in susceptible patients
• Withdrawal syndrome if abruptly stopped (confusion, fever, rhabdomyolysis - similar to neuroleptic malignant syndrome)

---

11. NURSING RESPONSIBILITIES

Before Administration (Pre-Drug)

1. Assess baseline vital signs - especially blood pressure (sitting and standing) to establish baseline for orthostatic hypotension monitoring
2. Review medical history - confirm no hypersensitivity, assess for psychiatric history, liver disease, renal function
3. Medication reconciliation - check for CYP1A2 inhibitors (fluoroquinolones, fluvoxamine), estrogens, dopamine antagonists (metoclopramide, antipsychotics) that can block ropinirole's effect
4. Assess for smoking status - smoking induces CYP1A2 and decreases ropinirole levels; changes in smoking habit require dose adjustment
5. Baseline neurological assessment - document motor function, sleep patterns, mood, and cognitive status
6. Pregnancy/lactation screening - assess reproductive status; educate that ropinirole can suppress prolactin and impair milk production

During Administration

1. Administer with food or milk to minimize nausea - the most common adverse effect
2. For RLS: Give dose 1-3 hours before bedtime only
3. Follow titration schedule strictly - do not increase dose faster than prescribed; rapid titration increases orthostatic hypotension risk
4. Never abruptly discontinue - taper per schedule to avoid withdrawal (NMS-like syndrome)

Monitoring / Ongoing Assessment

1. Monitor blood pressure in lying and standing positions - watch for orthostatic hypotension (fall in SBP >20 mmHg on standing); instruct patient to change positions slowly
2. Monitor for sleepiness and sleep attacks - warn patients not to drive or operate heavy machinery until they know how the drug affects them; ask about sudden-onset sleep without warning
3. Screen for impulse control disorders at every visit - ask directly about gambling, hypersexuality, binge eating; patients are often embarrassed and will not volunteer this information
4. Hallucinations and psychiatric changes - especially in elderly; report to physician immediately
5. Monitor for dyskinesia when used with levodopa - may require levodopa dose reduction
6. Liver function monitoring - particularly in patients with hepatic impairment

Patient and Family Education

1. Orthostatic precautions: Rise slowly from lying to sitting to standing; sit at the edge of the bed for 1-2 minutes before standing; use grab bars; call for assistance if dizzy
2. No abrupt discontinuation - emphasize that the drug must be tapered; missing doses or stopping suddenly can cause a dangerous withdrawal reaction
3. Avoid alcohol - potentiates CNS depression and hypotension
4. Report compulsive behaviors immediately (gambling, sexual urges, binge eating) - these are drug side effects and the dose may need to be adjusted
5. Sleep safety - do not drive or operate machinery if experiencing excessive daytime sleepiness or sudden sleep attacks
6. Smoking: Inform physician if starting or stopping smoking (affects drug metabolism)
7. Medication interactions - avoid antipsychotics (haloperidol, metoclopramide) as they are dopamine antagonists that can block ropinirole's therapeutic effect
8. Storage education: Store at room temperature, protect from light and moisture, keep tightly closed
9. Missed dose (PD): If almost time for next dose, skip missed dose - do not double up

---

QUICK REFERENCE SUMMARY TABLE

---